A Systemic Review: Nutrition Strategy, Neuroendocrine Control & Lifestyle in Polycystic Ovary Syndrome

Sayama Nadaf, Sushant Mohite, Suraj Jadhav, Dr. Bhagyesh Janugade, Alfiya Mujawar, Om Niprul, Sanika Mote, Sanika Mali,

doi:10.5281/zenodo.18894086

Review Paper | Open Access
Volume 04 | Issue 03 | Article Id IJPS/260402590

A Systemic Review: Nutrition Strategy, Neuroendocrine Control & Lifestyle in Polycystic Ovary Syndrome
Sayama Nadaf* Sushant Mohite Suraj Jadhav Dr. Bhagyesh Janugade Alfiya Mujawar Om Niprul Sanika Mote Sanika Mali
Krishna Foundation`s Jaywant Institute of Pharmacy, Wathar, Karad, Maharashtra 415539

Abstract

Polycystic ovary syndrome (PCOS) impacts 4-20% of women globally, featuring irregular periods, infertility, hirsutism, obesity, and cystic ovaries, while driving insulin resistance and risks like diabetes, cardiovascular issues, hypertension, dyslipidemia, and cancers due to unclear pathophysiology involving hypothalamic-pituitary-ovarian axis dysregulation. First- line management focuses on lifestyle shifts, including low-calorie, low-GI, high-fiber, omega- 3-rich, ketogenic, Mediterranean, antioxidant, and anti-inflammatory diets to enhance insulin sensitivity, hormonal balance, and weight. Ayurveda provides personalized, side-effect-free relief by targeting root causes—regularizing cycles, controlling blood sugar and weight, boosting fertility, and reducing stress—making nutrition strategies, neuroendocrine control, lifestyle changes, and Ayurvedic interventions key for effective PCOS symptom management.

Keywords

Nutrition strategy, Lifestyle in PCOS, Ayurvedic Medicines.

Introduction

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder in women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. It is not only a reproductive disorder but also a metabolic and neuroendocrine condition, associated with insulin resistance, obesity, and HPO-axis imbalance.

PCOD is a milder form where ovulation occurs irregularly, while PCOS involves chronic anovulation, high androgens, and greater metabolic risk.

HISTORICAL BACKGROUND

Ancient References (400 BCE – 1700s):

Ancient medical texts (like Hippocrates, ~400 BCE) described women with “masculine traits” such as infertility, irregular periods, and excessive hair growth. While not called PCOS then, these were likely early descriptions. In the 18th century, physicians began noticing enlarged ovaries during autopsies of women with menstrual and fertility problems.

The 19th Century: First Medical Observations

1844 – Dr. Chereau (France) described sclerocystic ovaries in women who had irregular menstruation and infertility.

1895 – Rokitansky noted the association between ovarian enlargement and abnormal menstrual cycles.These reports laid the groundwork for linking ovarian changes with reproductive disorders.

1935 – The Stein-Leventhal Syndrome:

Dr. Irving F. Stein Sr. and Dr. Michael L. Leventhal (Chicago, USA) published their landmark paper.They described seven women with Enlarged polycystic ovaries, Irregular or absent menstruation, Infertility & Hirsutism (excess hair growth). After performing bilateral ovarian wedge resections, 5 of the 7 women regained normal menstruation and some conceived.This condition became known as the Stein-Leventhal Syndrome.

Mid–20th Century (1940s–1970s): Endocrine Understanding

Doctors discovered that women with the syndrome often had high levels of luteinizing hormone (LH) and androgens (male hormones).The link with insulin resistance began to emerge by the late 1960s and 70s.By this point, PCOS was recognized not only as a reproductive disorder but also as a metabolic condition.

Late 20th Century (1980s–1990s): Modernization of Diagnosis

Ultrasound imaging made it possible to directly see “polycystic ovaries.” In 1990 (NIH Conference, USA),PCOS was defined as chronic anovulation + hyperandrogenism, after excluding other causes.

Fig 1.1 : Historical Background of PCOS

2003 (Rotterdam Criteria, Europe):

Diagnosis required two of three: Irregular ovulation/periods, High androgen levels (clinical or biochemical) or Polycystic ovaries on ultrasound

21st Century: Beyond Reproduction

PCOS is now recognized as a lifelong syndrome affecting not just fertility, but also metabolic health, mental health, and long-term risks (e.g., diabetes, cardiovascular disease).Research continues into genetics, insulin resistance, inflammation, and environmental triggers (like endocrine-disrupting chemicals).

TYPES OF PCOS

Based on Rotterdam criteria, PCOS is classified into four phenotypes:

Table 1.1 Types Of PCOS

	Phenotype A	Phenotype B	Phenotype C	Phenotype D
Hyperandrogenism & Hirsutisum	ü	ü	ü	û
Ovulatory dysfunction	ü	ü	ü	û
POMS	ü	û	û	û

PATHOPHYSIOLOGY

Abnormal GnRH secretion increases LH over FSH, stimulating ovarian androgen production. High androgens impair follicle development, causing anovulation, cyst formation, acne, and hirsutism.

Insulin resistance worsens androgen excess and leads to metabolic and reproductive dysfunction.

CAUSES

Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, typically during their reproductive years. The exact cause of PCOS is not fully understood, but several interrelated factors are believed to contribute to its development such as Hormonal imbalance (high androgens, low progesterone), Insulin resistance, Genetic predisposition, Inflammation, Lifestyle factors (diet, inactivity, stress), Obesity, thyroid disorders, adrenal dysfunction, vitamin D deficiency etc.

SYMPTOMS

PCOS include symptoms like Irregular or absent periods, Infertility, Hirsutism, acne, hair loss, Weight gain, insulin resistance, Anxiety and depression

HORMONAL CHANGES

Table 1.2: Hormonal Changes

Sr. No.	Hormone Change	Effect	Clinical Feature
1.	↑ Luteinizing Hormone (LH)	Stimulate Androgen Production	Hyperandrogenism
2.	↓ Follicle Stimulating Hormone (FSH)	Impair Follicle Maturation	Anovulation, Irregular Menstrution
3.	↑ Androgens	Excess Androgens	Hirsutism, Acne, Hair Loss
4.	↓ Sex Hormone- Binding Globulin	More Free Androgens	Exacerbated Hyperandrogenic Symptoms
5.	↑ Estrogens	Chronic Low-level Estrogen Secretion	Risk Of Endometrial Hyperplasia
6.	↑ Insulin	Worsens Hyperandrogenisum	Metabolic Issues

ROLE OF NUTRITION

A PCOS-friendly diet for example Low-GI, high-fiber carbohydrates ,Adequate protein and omega-3 fats ,Micronutrients like Vitamin D, B12, magnesium, zinc, chromium, selenium , also Mediterranean and plant-based diets improve insulin resistance and ovulation.

LIFESTYLE MANAGEMENT

Lifestyle modification is considered the first-line therapy for PCOS by international guidelines because it improves metabolic, hormonal, and reproductive outcomes. It includes 5–10% weight loss ,Regular exercise ,Healthy low-GI diet ,Adequate sleep (7–9 hours) ,Stress management (yoga, meditation)

AYURVEDIC MANAGEMENT

PCOS is related to Kapha and Vata imbalance in Ayurveda.Important herbs like Shatavari, Ashwagandha, Guduchi, Triphala, Fenugreek, Guggulu. These help in hormone balance, insulin sensitivity, weight control, and ovarian function. Panchakarma therapies detoxify and restore balance.

AYURVEDA vs ALLOPATHY

Ayurveda treats the root cause, improves lifestyle, and balances hormones naturally while Allopathy provides quick symptom control using drugs and hormones. Both systems are useful, but Ayurveda is especially beneficial for long-term PCOS management.

OBJECTIVE

To study the prevalence and incidence of PCOS among women of reproductive age in different populations.
To identify the underlying pathophysiological mechanisms involved in PCOS, including hormonal, genetic, and metabolic factors.
To evaluate the role of lifestyle factors (diet, exercise, stress) in the development and management of PCOS.
To assess the impact of PCOS on reproductive health, such as infertility, menstrual irregularities, and ovulatory dysfunction.
To investigate metabolic complications such as insulin resistance, obesity, and cardiovascular risk factors associated with PCOS.
To explore the psychological and emotional impact of PCOS, including anxiety, depression, and reduced quality of life.
To analyze the effectiveness of various treatment strategies, including pharmacological therapy, lifestyle modification, and complementary medicine.
To identify and validate biomarkers for early diagnosis and disease progression monitoring in PCOS.
To investigate the genetic and epigenetic basis of PCOS susceptibility and inheritance.
To develop and evaluate new therapeutic interventions for improving reproductive and metabolic outcomes in women with PCOS.

DISCUSSION

The study confirms that Polycystic Ovary Syndrome (PCOS) is a metabolic–endocrine disorder involving hormonal, metabolic, and ovarian abnormalities.

Hormonal Changes : It includes Increased LH and LH/FSH ratio (>2:1), Increased androgens (testosterone, DHEAS), Decreased progesterone and SHBG, Resulting in anovulation and menstrual irregularities.
- - - Metabolic Abnormalities : It includes Insulin resistance and hyperinsulinemia, High triglycerides and LDL, low HDL, Central obesity and inflammation (CRP, IL-6), Increased risk of diabetes and cardiovascular disease
    - Ultrasound Findings : It includes Multiple small follicles, Increased ovarian volume, Follicular arrest and stromal thickening
    - Clinical Features : It includes Irregular or absent periods, Hirsutism, acne, hair loss, Infertility, obesity, Anxiety, stress, and depression.

These findings confirm PCOS as a chronic endocrine–metabolic disorder, not just a reproductive problem.

PCOS develops due to neuroendocrine and metabolic imbalance. Excess GnRH → high LH → increased ovarian androgens, while insulin resistance further raises androgen levels and suppresses SHBG, leading to ovulation failure.

Lifestyle factors such as poor diet, obesity, and stress worsen hormonal imbalance. Even 5– 10% weight loss significantly improves ovulation and insulin sensitivity.

Role of Ayurvedic Herbs

Ayurveda views PCOS as Kapha–Vata imbalance with metabolic blockage. Herbs correct the root cause by improving metabolism, hormones, and ovarian function.

Table 1.3: Herbs and Actions

Herb	Main Role in PCOS
Shatavari	Regulates female hormones, improves ovulation
Ashwagandha	Reduces stress, balances cortisol and LH/FSH
Guduchi	Improves insulin sensitivity, reduces inflammation
Triphala	Detoxifies, improves metabolism and gut health
Fenugreek	Lowers insulin resistance and androgens
Kanchanar	Reduces cysts, supports thyroid and fat metabolism
Licorice	Lowers testosterone, improves acne & hirsutism
Gokshura	Supports ovarian and hormonal balance

PCOS is a multifactorial disorder involving hormonal imbalance, insulin resistance, ovarian dysfunction, and psychological stress.

Modern medicine controls symptoms, while Ayurvedic herbs correct metabolism, reduce androgens, improve ovulation, and support long-term hormonal balance.

An integrated approach of diet, exercise, stress control, modern therapy, and Ayurveda provides the best and most sustainable management of PCOS.

CONCLUSION

Polycystic Ovary Syndrome (PCOS) is a hormonal and metabolic disorder influenced by genetic and environmental factors. It disrupts the hypothalamic–pituitary–ovarian (HPO) axis, leading to high androgen levels, irregular ovulation, and insulin resistance. Therefore, PCOS management should focus on correcting these metabolic and neuroendocrine imbalances.

A balanced diet rich in low-glycemic foods, fiber, lean proteins, and omega-3 fatty acids helps improve insulin sensitivity, control weight, and regulate menstruation. Avoiding processed foods and sugars reduces inflammation and hormonal imbalance.

Stress management, proper sleep, yoga, and meditation help regulate hormones such as GnRH, LH, and FSH, supporting reproductive health. Regular physical activity further enhances insulin sensitivity and prevents long-term complications.

Ayurveda considers PCOS a disorder of Kapha and Vata imbalance. Treatments such as Panchakarma, herbal medicines like Shatavari, Ashwagandha, Guduchi, and Triphala, along with yoga and diet, help restore hormonal balance and ovarian function.

In conclusion, an integrated approach combining nutrition, lifestyle modification, and Ayurvedic therapy offers an effective natural strategy for managing PCOS and improving overall reproductive and metabolic health.

REFERENCES

Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology & Metabolism, 89(6), 2745–2749.
Adams, J., Polson, D. W., & Franks, S. (1986). Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal (Clinical Research Edition), 293(6543), 355–359.
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007). Polycystic ovary syndrome. The Lancet, 370(9588), 685–697.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25.
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta?analysis. Human Reproduction, 31(12), 2841–2855.
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284.
Rojas, J., Chávez, M., Olivar, L. C., Rojas, M., Morillo, J., Mejías, J., Calvo, M., & Bermúdez, V. (2014). Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. International Journal of Reproductive Medicine, 2014, 719050.
Barr, S., Hart, K., Reeves, S., Sharp, K., Jeanes, Y. M. (2019). Habitual dietary intake, eating patterns and food choices of women with polycystic ovary syndrome. European Journal of Nutrition, 58(8), 2803–2815.
National Institute of Ayurveda (2021). Ayurvedic management of reproductive disorders: Focus on PCOS. Ministry of AYUSH, Government of India.
Sharma, R., & Mishra, A. (2020). Ayurvedic perspective and management of Polycystic Ovary Syndrome (PCOS): A review. Journal of Ayurveda and Integrative Medicine, 11(4), 555–561.
Panda, A.K. & Kar, A. (2007). Bauhinia variegata leaf extract in thyroid dysfunctions in female rats. Journal of Ethnopharmacology, 110(3): 414–419.
Fiore, C., Eisenhut, M., Krausse, R., Ragazzi, E., Pellati, D., Armanini, D., & Bielenberg, J. (2008). Antiviral effects of Glycyrrhiza species. Phytotherapy Research, 22(2), 141–148.
Pastorino, G., Cornara, L., Soares, S., Rodrigues, F., & Oliveira, M. B. P. P. (2018). Liquorice (Glycyrrhiza glabra) root as an active ingredient in cosmetics: From traditional use to modern application. Phytotherapy Research, 32(12), 2323–2330.
Shah, S. L., Wahid, F., Ullah, H., & Khan, N. (2019). Chemical composition and pharmacological activities of Glycyrrhiza glabra L. International Journal of Pharmacognosy and Phytochemical Research, 11(3), 177–188.
Zhu, J., Chen, C., Zhang, B., & Huang, X. (2019). Licorice extract and glycyrrhizin improve endocrine and metabolic disorders in women with polycystic ovary syndrome: A systematic review. Journal of Ethnopharmacology, 235, 584–593.
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2013). Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 19(3), 271–283.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Lancet Diabetes & Endocrinology, 6(9), 714–726.
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009). Evidence-based and potential benefits of physical activity in polycystic ovary syndrome. Clinical Endocrinology, 70(6), 828– 835.
Bhavaprakasha Nighantu – Commentary on Classical Ayurvedic Herbs, Chaukhamba Publications, 2019.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004).Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Human Reproduction, 19(1), 41–47.
Azziz, R., Carmina, E., Dewailly, D., et al. (2006). Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. Journal of Clinical Endocrinology & Metabolism, 91(11), 4237–4245.
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016).Criteria, prevalence, and phenotypes of polycystic ovary syndrome.Fertility and Sterility, 106(1), 6–15.
Carmina, E., & Azziz, R. (2019).Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.Fertility and Sterility, 112(2), 220–225.
Dumesic, D.A., Oberfield, S.E., Stener-Victorin, E., Marshall, J.C., Laven, J.S., & Legro, R.S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews, 36(5), 487–525.
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 106(1), 6–15.
Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome: The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37(5), 467–520.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602–1618.
Norman, R. J., Noakes, M., Wu, R., Davies, M. J., Moran, L. J., & Wang, J. X. (2004). Improving reproductive performance in obese women with polycystic ovary syndrome. Human Reproduction Update, 10(3), 267–280.
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. Endocrine Reviews, 36(5), 487–525.
González, F., Nair, K. S., & Sia, C. L. (2012). Insulin sensitivity and metabolic inflammation in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4783–4793.
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015). Complications and challenges associated with polycystic ovary syndrome: Current perspectives. International Journal of Women’s Health, 7, 745–763.
Tripathi, Y. B., et al. (2015). Clinical Evaluation of Kanchanar Guggulu in Polycystic Ovarian Disease. AYU Journal, 36(3), 345–351.
Rao, M., et al. (2018). Role of Ayurvedic Herbs in Hormonal and Metabolic Modulation in PCOS: A Review. Journal of Ayurveda and Integrative Medicine, 9(4), 241–249.
Upadhyay, A.K., et al., Phytochemistry and pharmacological activities of Asparagus racemosus: A review, Journal of Herbal Medicine, 2010.
Auddy, B., et al., A standardized Withania somnifera extract significantly reduces stress- related parameters in adults: a double-blind, randomized, placebo-controlled study, J Clin Psychiatry, 2008.
Sengupta R, et al. Tinospora cordifolia ameliorates insulin resistance and oxidative stress in metabolic disorders. Indian J Pharmacol. 2011.
Adaikan, P. G., Gauthaman, K., & Prasad, R. N. V. (2000). Proerectile pharmacological effects of Tribulus terrestris extract on the rabbit corpus cavernosum. Annals of the Academy of Medicine, Singapore, 29(1), 22–26.
Patel, D., et al. (2016). Phytochemical and pharmacological profile of Trigonella foenum- graecum: An overview. International Journal of Pharmacy and Pharmaceutical Sciences, 8(9), 13–19.
Peterson CT et al. “Therapeutic uses of Triphala in Ayurvedic medicine.” J Altern Complement Med. 2017;23(8):607–614.
Mirza, F. G., Tahlak, M. A., Rjeili, R. B., Hazari, K. S., Ennab, F., Hodgman, C., Khamis, A. H., & Atiomo, W. U. (2022). Polycystic Ovarian Syndrome (PCOS): Does the challenge end at conception? International Journal of Environmental Research and Public Health, 19(22), 14914.